Inhibitors of stone formation

Seminars in Nephrology

Volumn 16, Issue 5, 1996, Pages 474-486

  Worcester, Elaine M ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSAMINOGLYCAN; OSTEOPONTIN; PHOSPHOPROTEIN; TAMM HORSFALL GLYCOPROTEIN; ULINASTATIN;

CALCIUM OXALATE STONE; CRYSTALLIZATION; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; STONE FORMATION; URINE;

CALCIUM OXALATE; CRYSTALLIZATION; HUMANS; URINARY CALCULI;

EID: 0029778389     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Lemann J Jr, Pleuss JA, Worcester EM, et al: Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Int 49:200-208, 1996
2. Costello J, Landwehr DM: Determination of oxalate concentration in blood. Clin Chem 34:1540-1544, 1988
3. Soucie JM, Thun MJ, Coates RJ, et al: Demographic and geographic variability of kidney stones in the United States. Kidney Int 46:893-899, 1994
4. Thomas WC, Howard JE: Studies on the mineralizing propensity of urine from patients with and without renal calculi. Trans Assoc Am Physicians 72:181-187, 1959
5. Elliott JS, Rabinowitz IN: Calcium oxalate crystalluria: Crystal size in urine. J Urol 121:324-327, 1980
6. Kok DJ, Shan SR: Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847-854, 1994
7. Riese RJ, Riese JW, Kleinman JG, et al: Specificity in calcium oxalate adherence to papillary epithelial cells in culture. Am J Physiol 255:F1025-F1032, 1988
8. Lieske JC, Walsh-Reitz MM, Toback FG: Calcium oxalate monohydrate crystals are endocytosed by renal epithelial cells and induce proliferation. Am J Physiol 262:F622-F630, 1992
9. Pak CYC, Holt K: Nucleation and growth of brushite and calcium oxalate in urine of stone-formers. Metabolism 25:665-673, 1976
10. Meyer JL, Smith HL: Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest Urol 13:36-39, 1975
11. Ryall RL, Harriett RM, Marshall VR: The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112:349-356, 1981
12. Robertson WG, Peacock M: Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 43:499-506, 1972
13. Robertson WG, Peacock M, Marshall RW, et al: Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med 294:249-252, 1976
14. Nakagawa Y, Abram V, Kezdy FJ, et al: Purification and characterization of the principal inhibitor of calcium oxalate monohydrate crystal growth in human urine. J Biol Chem 258:12594-12600, 1983
15. Coe FI, Parks JH, Nakagawa Y: Protein inhibitors of crystallization. Semin Nephrol 11:98-109, 1991
16. Nakagawa Y, Margolis HC, Yokoyama S, et al: Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium. J Biol Chem 256:3936-3944, 1981
17. Nakagawa Y, Renz CL, Ahmed M, et al: Isolation of nephrocalcin from kidney tissue of nine vertebrate species. Am J Physiol 260:F243-F248, 1991
18. 31P-NMR spectrometer. FEBS Lett 259:187-190, 1989
19. Sirivongs D, Nakagawa Y, Vishny WK: Evidence that mouse renal proximal tubule cells produce nephrocalcin. Am J Physiol 257:F390-F398, 1989
20. Davison JM, Nakagawa Y, Coe FL, et al: Increases in urinary inhibitor activity and excretion of an inhibitor of crystalluria in pregnancy: A defense against the hypercalciuria of normal gestation. Hypertension in Pregnancy 12:25-35, 1993
21. Nakagawa Y, Sirivongs D, Novy MB, et al: Nephrocalcin: biosynthesis by human renal carcinoma cells in vitro and in vivo. Cancer Res 52:1573-1579, 1992
22. Nakagawa Y, Abram V, Parks JH, et al: Urine glycoprotein crystal growth inhibitors: Evidence for a molecular abnormality in calcium oxalate nephrolithiasis. J Clin Invest 76:1455-1462, 1985
23. Worcester EM, Nakagawa Y, Wabner CL, et al: Crystal adsorption and growth slowing by nephrocalcin, albumin, and Tamm-Horsfall protein. Am J Physiol 255:F1197-F1205, 1988
24. Deganello S: Interaction between nephrocalcin and calcium oxalate monohydrate: A structural study. Calcif Tissue Int 48:421-428, 1991
25. Asplin J, DeGanello S, Nakagawa YN, et al: Evidence that nephrocalcin and urine inhibit nucleation of calcium oxalate monohydrate crystals. Am J Physiol 261:F824-F830, 1991
26. Tiselius H-G, Bek-Jensen H, Fomander A-M, et al: Crystallization properties in urine from calcium oxalate stone formers. J Urol 154:940-946, 1995
27. Hess B, Nakagawa Y, Coe FL: Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99-F106, 1989
28. Lieske JC, Leonard R, Toback FG: Adhesion of calcium oxalate monohydrate crystals to renal epithelial cells is inhibited by specific anions. Am J Physiol 268:F604-F612, 1995
29. Hess B: Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393-398, 1994
30. Kumar S, Muchmore A: Taram-Horsfall protein - uromodulin (1950-1990). Kidney Int 37:1395-1401, 1990
31. McQueen EG, Engel GB: Factors determining the aggregation of urinary mucoprotein. J Clin Pathol 19:392-396, 1966
32. Hess B: The role of Tamm-Horsfall glycoprotein and nephrocalcin in calcium oxalate monohydrate crystallization processes. Scanning Microsc 5:689-696, 1991
33. Lieske JC, Toback FG: Regulation of renal epithelial cell endocytosis of calcium oxalate monohydrate crystals. Am J Physiol 264:F800-F807, 1993
34. McKee MD, Nanci A, Khan SR: Ultrastructural immunodetection of osteopontin and osteocalcin as major matrix components of renal calculi. J Bone Miner Res 10:1913-1929, 1995
35. Shiraga H, Min W, VanDusen WJ, et al: Inhibition of calcium oxalate crystal growth in vitro by uropontin: Another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426-430, 1992
36. Worcester EM, Blumenthal SS, Beshensky AM, et al: The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 7:1029-1036, 1992
37. Rodan GA: Osteopontin overview. Ann N Y Acad Sci 760:1-5, 1995
38. Butler WT: The nature and significance of osteopontin. Connect Tissue Res 23:123-136, 1989
39. Fitzpatrick LA, Ingram R, Severson A, et al: Matrix proteins associated with calcification are present in human coronary arteries. Clin Res 41:657A, 1993
40. Kohri K, Suzuki Y, Yoshida K, et al: Molecular cloning and sequencing of cDNA encoding urinary stone protein, which is identical to osteopontin. Biochem Biophys Res Commun 184:859-864, 1992
41. Yamamoto S, Hijiya N, Setoguchi M, et al: Structure of the osteopontin gene and its promoter. Ann N Y Acad Sci 760:44-58, 1995
42. Hoyer JR: Uropontin in urinary calcium stone formation. Miner Electrolyte Metab 20:385-392, 1994
43. Nagata T, Todescan R, Goldberg HA, et al: Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. Biochem Biophys Res Commun 165:234-240, 1989
44. Singh K, DeVouge MW. Mukherjee BB: Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chem 265:18696-18701, 1990
45. 3 stimulates synthesis and secretion of nonphosphorylated osteopontin (secreted phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res 51:2144-2150, 1991
46. Kleinman JG, Beshensky A, Worcester EM, et al: Expression of osteopontin, a urinary inhibitor of stone mineral crystal growth, in rat kidney. Kidney Int 47:1585-1596, 1995
47. Worcester EM, Beshensky AM: Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci 760:375-377, 1995
48. Worcester EM, Snyder C, Beshensky AM: Osteopontin inhibits heterogeneous nucleation of calcium oxalate. J Am Soc Nephrol 3:956, 1995
49. Boskey AL: Osteopontin and related phosphorylated sialoproteins: Effects on mineralization. Ann N Y Acad Sci 760:249-256, 1995
50. Asplin JR. Hoyer J, Gillespie C, et al: Uropontin (UP) inhibits aggregation of calcium oxalate monohydrate (COM) crystals. J Am Soc Nephrol 6:941, 1995
51. Wesson JA, Worcester E, Kleinman J, et al: Inhibitor proteins in urine favor formation of calcium oxalate dehydrate (COD) crystals, which have a smaller affinity for renal tubule cells than monohydrate (COM) crystals. J Am Soc Nephrol 3:956, 1995
52. Doyle IR, Ryall RL, Marshall VR: Inclusion of proteins into calcium oxalate crystals precipitated from human urine: A highly selective phenomenon. Clin Chem 37:1589-1594, 1991
53. Stapleton AMF, Simpson RJ, Ryall RL: Crystal matrix protein is related to human prothrombin. Biochem Biophys Res Commun 195:1199-1203, 1993
54. Stapleton AMF, Ryall RL: Crystal matrix protein - getting blood out of a stone. Miner Electrolyte Metab 20:299-409, 1994
55. Doyle IR, Marshall VR, Dawson CJ, et al: Calcium oxalate crystal matrix extract: The most potent macromolecular inhibitor of crystal growth and aggregation yet tested in undiluted human urine in vitro. Urol Res 23:53-62, 1995
56. Stapleton AMF, Seymour AE, Brennan JS, et al: Immunohistochemical distribution and quantification of crystal matrix protein. Kidney Int 44:817-824, 1993
57. Atmani F, Lacour B, Strecker G, et al: Molecular characteristics of uronic-acid-rich protein, a strong inhibitor of calcium oxalate crystallization in vitro. Biochem Biophys Res Commun 191:1158-1165, 1993
58. Jessen TE, Faarvang KL, Ploug M: Carbohydrate as covalent crosslink in human inter-a-trypsin inhibitor: A novel plasma protein structure. FEBS Lett 230:195-200, 1988
59. Pillay NS, Asplin JR, Coe FL: S100 protein inhibits aggregation and growth of calcium oxalate monohydrate (COM) crystals, and is likely to be of physiological significance in urine. J Am Soc Nephrol 6:953, 1995
60. 3 crystal growth. Eur J Clin Invest 22:469-474, 1992
61. Hesse A, Wuzel H, Vahlensieck W: Significance of glycosaminoglycans for the formation of calcium oxalate stones. Am J Kidney Dis 17:414-419, 1991
62. Suzuki K, Mayne K, Doyle IR, et al: Urinary glycosaminoglycans are selectively included into calcium oxalate crystals precipitated from whole human urine. Scanning Microsc 8:523-530, 1994
63. Ryall RL, Harnett RM, Hibberd CM, et al: Effects of chondroitin sulphate, human serum albumin and Tamm-Horsfall mucoprotein on calcium oxalate crystallization in undiluted human urine. Urol Res 19:181-188, 1991
64. Lieske JC, Hammes MS, Toback FG, et al: Calcium oxalate monohydrate (COM) crystals stimulate osteopontin (OPN) gene expression and protein secretion by renal epithelial cells. J Am Soc Nephrol 6:951, 1995
65. Nakagawa Y, Ahmed M, Hall SL, et al: Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. J Clin Invest 79:1782-1787, 1987
66. Addadi L, Weiner S: Interactions between acidic proteins and crystals: Stereochemical requirements in biomineralization. Proc Natl Acad Sci USA 82:4110-4114, 1985
67. Wheeler AP, George JW, Evans CA: Control of calcium carbonate nucleation and crystal growth by soluble matrix of oyster shell. Science 212:1397-1398, 1981
68. Tiselius H-G, Berg C, Fornander A-M, et al: Effects of citrate on the different phases of calcium oxalate crystallization. Scanning Microsc 7:381-390, 1993
69. Hess B, Nakagawa Y, Parks JH, et al: Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569-F578, 1991
70. Hess B, Zipperle L, Jaeger P: Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784-F791, 1993
71. Hess B, Jaggi M, Zipperle L, et al: Reduced carbohydrate content of Tamm-Horsfall glycoprotein (THP) from severely recurrent renal calcium stone formers (RCSF). J Am Soc Nephrol 6:949, 1995
72. Atmani F, Lacour B, Jungers P, et al: Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers. Urol Res 22:257-260, 1994
73. Worcester EM: Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol 5:S46-S53, 1994
74. Porile J, Asplin J, Nakagawa Y, et al: Impaired crystal growth inhibition does not explain accelerated calcium oxalate monohydrate (COM) nephrolithiasis (NL). J Am Soc Nephrol 4:713, 1993